How do you counsel patients with GCA on the benefits of steroids who have already experienced vision loss?

I first tell the patient they are at considerable risk for further visual loss in the same eye or the other eye over the next 1-2 weeks.

I also let them know that, even though their risk of visual loss has been reduced, their best option for preventing further visual loss is immediately starting high-dose corticosteroids. But even with this, they have about a 20% chance of their vision worsening over the next 1-2 weeks - so they are not yet "out of the woods." I also let them know that the steroids reduce inflammation in their blood vessels and that their visual loss is not likely to improve. However, their other symptoms should markedly improve over the next 24-48 hours.

Next, we discuss the well-known side effects of steroids. I try to im...

Dr. @Dr. First Last has lucidly outlined a time-tested, effective, and clinically proven regimen for GCA that underscores the unenviable limitations of prescribing a prolonged steroid taper for elderly (ouch! my age) patients with GCA. If started after an acute steroid "cool-down," Tocilizumab/IL-6 blockers may "spare" the patient steroid side effects.

I don't know if this is an East Coast problem, but in many of the patients referred to me as GCA with visual loss, the diagnosis is murky. I need at least 3 things to establish GCA with visual loss: 1- the swollen disc of AION, 2- temporal artery biopsy with giant cells, fragmented internal elastic media, etc., 3- elevated sed rate/CRP. The referral usually confirms #3, but the other two may...

Agree wholeheartedly with Dr. @Dr. First Last's comments. I would add one thing I do to mitigate long-term corticosteroid side effects. I taper every other day, e.g., from 60 mg daily to 70-30, then 70-10, then to 60 every other day, and so on. This speeds up achieving every other day steroids, which mitigates steroid toxicity.

In my experience, steroid taper is often dependent on the patient's comorbidities. Those with rheumatological issues get shared with that service; those with DM get shared with their PMD. Communication with other services is key, especially when treating with tocilizumab. I manage about a third of GCA patients independently. Those patients may be on steroids for up to a year or more. I DO alternate doses during taper, especially when the patient has excess oral medications. I let them break the tablets and alternate days. This is quite effective. Everything is done on an individual basis. I also follow some very established patients remotely and depend on transmission of lab values when altering steroid dose even when they are out of state....

It’s really hard but it’s similar to being with the patient through other hard times, such as if they had vision loss from a stroke. Our goal is clear - we want to prevent another stroke. Although vision loss is horrible, we have to focus on the positives - the stroke wasn’t fatal, and they’re not paralyzed or wheelchair dependent. This is very difficult for most people to recognize or adjust to shortly after a major life-changing event, and it will take time, but I tell them that time can heal.

Post-stroke depression is a very well-documented phenomenon, and I’m certain the same could be said for GCA or any other disease that leads to lifelong loss of function. So I also try to assess their coping skills, and to tell them not to be too har...

My preferred approach is a gradual, dose-dependent reduction of the daily glucocorticoid regimen rather than transitioning to alternate-day dosing. In patients with giant cell arteritis, I consider sustained suppression of vascular inflammation particularly important, given the potential for recurrent cranial ischemia and irreversible neuro-ophthalmic complications.

I generally favor a response-guided taper, with the magnitude of each dose reduction becoming progressively smaller as the patient approaches lower maintenance doses. This strategy allows for a more controlled assessment of disease activity while minimizing unnecessary cumulative glucocorticoid exposure.

An important consideration is that clinical remission should not be determi...